Michael is the President and Founder of the Fatty Liver Alliance and has been a leader in the area of liver disease, in both commercial and not-for-profit organizations for over 30 years. He is based in Toronto, where he passionately increases the visibility of MASLD AND MASH and advocates for more research and resources to help patients in need.

Michael is a passionate advocate for those living with fatty liver disease and is dedicated to improving the lives of those affected by the condition. He has been instrumental in organizing events and initiatives to educate and inform the public about the disease and its impact on individuals and families. He was a Director on the board of a Canadian liver focused charity for 9 years (National Marketing and Communications Committee Member. Strategy Committee Member).

In addition to his work with Fatty Liver Alliance, Michael is also a respected speaker and commentator on fatty liver disease and related topics. He has been featured in various media outlets, including newspapers, radio, and television, and has spoken at conferences and other events to raise awareness about the disease.

He has held senior leadership roles including a Business Unit Director in Virology and Oncology at Hoffmann-La Roche, Director of Donor Relations at Canadian Blood Services, and as a sales and marketing leader at Schering-Plough.

He is the Chair for the Global Liver Institute’s Liver Action Network, and in 2024 was awarded, by GLI, the Global Excellence in Advocacy Award. Michael is a member of community advisory boards for the Canadian Association for the Study of the Liver (CASL), Regeneron’s NASH POWER Council, and PPD/Evidera Patient Voice in NASH Patient Advisory Board (PAB). Michael was an AASLD collaborator on the Fatty Liver Disease Research and Action Priorities consensus statement, an EASL participant in NASH consensus statement development, an AASLD participant at the Delphi expert panel developing consensus around the nomenclature of NAFLD.

He participates as a stakeholder at Mosaic (A multi-stakeholder multi-specialty NASH Trialists Think Tank), and is a member of the Liver Forum for Collaborative Research, and the Global NASH Council.